Home
Forums
New posts
Search forums
What's new
New posts
Latest activity
Members
Current visitors
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Home
Forums
Brown Cafe Community Center
Current Events
Coronavirus
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="El Correcto" data-source="post: 4988171" data-attributes="member: 60631"><p>“However, these results should be interpreted with caution. Firstly, it is important to note that the drug was only tested <em>in vitro</em> using a single line of monkey kidney cells engineered to express human signaling lymphocytic activation molecule (SLAM), also known as CDw150, which is a receptor for the measles virus [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0050" target="_blank">10</a>]. Also, ivermectin has not been tested in any pulmonary cell lines, which are critical for SARS-CoV-2 in humans [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0055" target="_blank">11</a>]. Furthermore, these authors did not show whether the reduction seen in RNA levels of SARS-CoV-2 following treatment with ivermectin would indeed lead to decreased infectious virus titers. Importantly, the drug concentration used in the study (5 μM) to block SARS-CoV-2 was 35-fold higher than the one approved by the FDA for treatment of parasitic diseases, which raises concerns about its efficacy in humans using the FDA approved dose in clinical trials [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0060" target="_blank">12</a>].”</p><p></p><p>“Despite its promising antiviral and preliminary anti-inflammatory potential, the development of ivermectin formulations presents challenges, primarily due to its property of poor water solubility. Consequently, ivermectin's oral bioavailability remains low [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0140" target="_blank">28</a>]. In addition, its pharmacokinetic profile may be affected by specific formulations, and minor differences in formulation design can modify plasma kinetics, biodistribution, and, consequentially, efficacy. For instance, ivermectin does not achieve adequate concentration levels in the human bloodstream necessary for treatment efficacy against ZIKV [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0145" target="_blank">29</a>]. Therefore, novel delivery strategies are needed to optimize ivermectin bioavailability.”</p><p></p><p>“We hypothesize that micro- and nanotechnology-based systems for the pulmonary delivery of ivermectin may offer opportunities for accelerating the clinical re-purposing of this “enigmatic drug” in the context of SARS-CoV-2 infection, as recent advances in pharmaceutical technology and nanomaterials can be applied to the treatment of pulmonary infections [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0120" target="_blank">[24]</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0125" target="_blank">[25]</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0130" target="_blank">[26]</a>,<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0180" target="_blank">[36]</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0185" target="_blank">[37]</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0190" target="_blank">[38]</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0195" target="_blank">[39]</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0200" target="_blank">[40]</a>]. Despite the challenges faced in developing these drug delivery carriers, and uncertainty with regard to the efficacy of ivermectin, it indeed presents promising potential. In an optimistic scenario, new drug dosage forms may not only contribute to mitigate SARS-CoV-2 infection, but also be effective against other emerging viral diseases.”</p><p></p><p>It seems to me there are a lot of issues with just running out and grabbing a tube of ivermectin to start taking huge doses of. Ivermectin also has POTENTIAL though.</p></blockquote><p></p>
[QUOTE="El Correcto, post: 4988171, member: 60631"] “However, these results should be interpreted with caution. Firstly, it is important to note that the drug was only tested [I]in vitro[/I] using a single line of monkey kidney cells engineered to express human signaling lymphocytic activation molecule (SLAM), also known as CDw150, which is a receptor for the measles virus [[URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0050']10[/URL]]. Also, ivermectin has not been tested in any pulmonary cell lines, which are critical for SARS-CoV-2 in humans [[URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0055']11[/URL]]. Furthermore, these authors did not show whether the reduction seen in RNA levels of SARS-CoV-2 following treatment with ivermectin would indeed lead to decreased infectious virus titers. Importantly, the drug concentration used in the study (5 μM) to block SARS-CoV-2 was 35-fold higher than the one approved by the FDA for treatment of parasitic diseases, which raises concerns about its efficacy in humans using the FDA approved dose in clinical trials [[URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0060']12[/URL]].” “Despite its promising antiviral and preliminary anti-inflammatory potential, the development of ivermectin formulations presents challenges, primarily due to its property of poor water solubility. Consequently, ivermectin's oral bioavailability remains low [[URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0140']28[/URL]]. In addition, its pharmacokinetic profile may be affected by specific formulations, and minor differences in formulation design can modify plasma kinetics, biodistribution, and, consequentially, efficacy. For instance, ivermectin does not achieve adequate concentration levels in the human bloodstream necessary for treatment efficacy against ZIKV [[URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0145']29[/URL]]. Therefore, novel delivery strategies are needed to optimize ivermectin bioavailability.” “We hypothesize that micro- and nanotechnology-based systems for the pulmonary delivery of ivermectin may offer opportunities for accelerating the clinical re-purposing of this “enigmatic drug” in the context of SARS-CoV-2 infection, as recent advances in pharmaceutical technology and nanomaterials can be applied to the treatment of pulmonary infections [[URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0120'][24][/URL], [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0125'][25][/URL], [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0130'][26][/URL],[URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0180'][36][/URL], [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0185'][37][/URL], [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0190'][38][/URL], [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0195'][39][/URL], [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/#bb0200'][40][/URL]]. Despite the challenges faced in developing these drug delivery carriers, and uncertainty with regard to the efficacy of ivermectin, it indeed presents promising potential. In an optimistic scenario, new drug dosage forms may not only contribute to mitigate SARS-CoV-2 infection, but also be effective against other emerging viral diseases.” It seems to me there are a lot of issues with just running out and grabbing a tube of ivermectin to start taking huge doses of. Ivermectin also has POTENTIAL though. [/QUOTE]
Insert quotes…
Verification
Post reply
Home
Forums
Brown Cafe Community Center
Current Events
Coronavirus
Top
